MINNEAPOLIS, MN- April 6, 2020 -The University of Minnesota has pioneered the development of promising cell-based cancer immunotherapy called FT596, and today announced opening Phase 1 clinical trial using FT596 for treatment of Relapsed/refractory B cell lymphoma and chronic lymphocytic leukemia. The U of M is the first location in the world to open this innovative treatment.
The Masonic Cancer Center team is saddened by the loss of Clara D. Bloomfield, MD, a pioneer in oncology at the University of Minnesota and a longtime cancer-researcher and administrator at prestigious institutions around the country. We were able to welcome her back home in 2016 when she was a featured speaker for our 7th Annual Cancer Research Symposium.
Madam Chair and members of the Committee-
Each year the Randy Shaver Cancer Research & Community Fund awards grants to groups across the state of Minnesota that are working to reduce the burden of cancer.
The mission of the Randy Shaver Cancer Research and Community Fund is to support the cancer community in Minnesota by funding research, prevention, treatment and other programs relating to the cancer community’s needs.
Institute's Dr. Ilana Chefetz will lead innovative study to help young women
Author: Angel Mendez, UMN Medical School Communications Manager | FEBRUARY 7, 2020
February is National Cancer Prevention Month. In Minnesota, there are an estimated 142,369 new cancer cases every year.
Professor Timothy Church with the University of Minnesota answers questions on lifestyle changes people can make to reduce their risk of getting cancer.
While February 4th was World Cancer Day, the entire month of February is honored as National Cancer Prevention Month. Cancer is an invasive and devastating disease that can affect anyone, regardless of age, gender, or race. Fortunately, the American Cancer Society has reported that cancer rates have gradually dropped since the 1990s.